Key result
Portico TAVR achieves ~100% procedural success, significantly reducing 30-day transaortic gradients.
Why the study?
Suboptimal prosthesis positioning during transcatheter aortic valve replacement may cause paravalvular regurgitation, conduction block, and mitral or coronary compromise, necessitating evaluation of a new repositionable valve.
Does transcatheter aortic valve replacement with the repositionable Portico valve improve hemodynamics and clinical status in patients with severe symptomatic aortic stenosis?
Does transcatheter aortic valve replacement with the repositionable Portico valve improve hemodynamics and clinical status in patients with severe symptomatic aortic stenosis?
TAVR with the repositionable Portico valve is feasible and provides good short-term hemodynamic and clinical outcomes, including a low rate of paravalvular regurgitation and no need for permanent pacemakers in this initial series.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The ability to reposition the valve may be helpful in reducing the likelihood of problematic paravalvular regurgitation, coronary obstruction, mitral interference, and atrioventricular block.”
Supports Portico valve feasibility in severe aortic stenosis; leaves open safety, durability, and efficacy in larger trials.
OBJECTIVES: The purpose of this study was to demonstrate the feasibility and procedural outcomes with a new self-expanding and repositionable transcatheter heart valve. BACKGROUND: Transcatheter aortic valve replacement is a viable option for selected patients with severe symptomatic aortic stenosis. However, suboptimal prosthesis positioning may contribute to paravalvular regurgitation, atrioventricular conduction block, and mitral or coronary compromise. METHODS: The repositionable Portico valve (St. Jude Medical, Minneapolis, Minnesota) was implanted in 10 patients with severe aortic stenosis utilizing percutaneous femoral arterial access. Patients underwent transthoracic and transesophageal echocardiography and multidetector computed tomography before and after valve implantation. Clinical and echocardiographic follow-up was obtained at 30 days. RESULTS: Device implantation was successful in all patients. Prosthesis recapture and repositioning was performed in 4 patients. Intermittent prosthetic leaflet dysfunction in 1 patient required implantation of a second transcatheter valve. There was 1 minor stroke. At 30-day follow-up, echocardiographic mean transaortic gradient was reduced from 44.9 ± 16.7 mm Hg to 10.9 ± 3.8 mm Hg (p < 0.001), and valve area increased from 0.6 ± 0.1 cm(2) to 1.3 ± 0.2 cm(2) (p < 0.001). Paravalvular regurgitation was mild or less in 9 patients (90%) and moderate in 1 patient (10%). There were no major strokes, major vascular complications, major bleeds, or deaths. No patient required pacemaker implantation. All patients were in New York Heart Association functional class II or less. CONCLUSIONS: Transcatheter aortic valve replacement with the repositionable Portico transcatheter heart valve is feasible, with good short-term clinical and hemodynamic outcomes.
No takes yet. Share an insight, caveat, or question.
Willson et al. (2012) studied severe aortic stenosis (n=10). Repositionable Portico transcatheter heart valve was evaluated on successful device implantation. Transcatheter aortic valve replacement with the Portico valve was successful in 100% of patients, reducing the mean transaortic gradient to 10.9 mm Hg at 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: